<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01243047</url>
  </required_header>
  <id_info>
    <org_study_id>COL012</org_study_id>
    <nct_id>NCT01243047</nct_id>
  </id_info>
  <brief_title>Intermittent Versus Continuous Tarceva Study</brief_title>
  <official_title>Intermittent Versus Continuous Erlotinib With Concomitant Modified 'Xelox' (q3W) in First-line Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized phase II study comprising of two treatment arms in patients who are
      previously untreated for metastatic or recurrent colorectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate two different schedules of erlotinib in combination with a modified XELOX regimen
      in terms of response rate
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate two different schedules of erlotinib in combination with a modified XELOX regimen in terms of response rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate two different schedules of erlotinib and modified XELOX regimen in terms of toxicity, their duration of response and effect on time to progression, progression-free survival and overall survival.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effect of intermittent versus continuous erlotinib administration on pharmacodynamic endpoints using tumor biopsies</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous erlotinib administration (21-day cycle). Erlotinib dose given at 100mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intermittent erlotinib administration (21-day cycle). Erlotinib dose given at 150mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>Erlotinib, Oxaliplatin, Capecitabine</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  ECOG performance status of 0-2.

          -  Histological proof of adenocarcinoma of colon or rectum with evidence of metastatic
             disease.

          -  At least one unidimensionally measurable lesion with a diameter &gt;20 mm using
             conventional CT or MRI scans, or &gt; 10 mm with spiral CT

          -  No prior drug treatment or chemotherapy for metastatic disease.

          -  No prior HER2 or EGFR inhibitors. No prior Oxaliplatin in any clinical setting.

          -  Absolute granulocyte count &gt; 1.5 x 109/L, platelet count &gt; 100 x 109/L, hemoglobin
             level &gt; 9.0 g/L, INR &lt; 1.5.

          -  Adequate renal &amp; hepatic functions: serum creatinine &lt; 1.5 x upper limit of normal
             (ULN) or calculated creatinine clearance &gt; 50ml/min, serum bilirubin &lt; 1.5 x ULN, ALT
             &lt; 2.5 x ULN or &lt; 5 x ULN in case of liver metastases, albumin level &gt; 30g/dL).

          -  Prior adjuvant or neoadjuvant chemotherapy for non-metastatic CRC is allowed if &gt; 3
             months has elapsed since the last dose of chemotherapy.

          -  Prior open surgery is allowed if &gt; 28 days* has elapsed since the date of surgery,
             wound healing is satisfactory and recovery from any complications from the surgery is
             adequate. (*For laparoscopic surgery, &gt; 14 days from the date of surgery).

          -  No serious medical conditions such as myocardial infarction within 6 months prior to
             entry, or any other medical conditions that might be aggravated by treatment

        Exclusion Criteria:

          -  Prior history of any malignancies, except basal cell cancer of skin, cervical CIN.

          -  Treatment with radiotherapy &lt; 30 days.

          -  Pregnant or lactating females

          -  Sexually active males and females (of childbearing potential) unwilling to practice
             contraception during the study.

          -  Patients who have not recovered from surgery or other medical illness such as
             infection.

          -  Evidence of central nervous system disease. Patients with a history of uncontrolled
             seizures, central nervous disorders or psychiatric disability judged by the
             investigator to be clinically significant precluding informed consent or interfering
             with compliance for oral drug intake should be excluded from the study

          -  Patients lacking physical integrity of upper gastrointestinal tract or malabsorption
             syndrome or unable to swallow tablets.

          -  Prior unanticipated severe reaction to fluoropyrimidine therapy (with or without
             documented DPD deficiency).

          -  Interstitial pneumonia or extensive symptomatic fibrosis of the lungs.

          -  Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or
             chemically related analogues, such as brivudine.

          -  Known peripheral neuropathy ≥ NCI CTC grade 1.

          -  Current or recent (within 10 days prior to study treatment start) use of full-dose
             oral anticoagulant (e.g. warfarin) or thrombolytic agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigette Ma, MD, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Oncology, The Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Oncology, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2010</study_first_posted>
  <last_update_submitted>November 20, 2012</last_update_submitted>
  <last_update_submitted_qc>November 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>CCTU</investigator_full_name>
    <investigator_title>Comprehensive Clinical Trial Unit</investigator_title>
  </responsible_party>
  <keyword>Second line treatment for metastatic colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

